

# Appendix

## List of variables in the models

Variable	Definition
$T_{H[r]}$	Resting $T_H$ cells
$T_{H[a]}$	Activated $T_H$ cells
$T_{H[w]}$	$T_H$ cells infected with the wild-type virus
$T_{H[48]}$	$T_H$ cells infected with the full T-cell ( $T_H$ /CTL)-escape mutant
$T_{C[r]}$	Resting CTLs
$T_{C[Pr1]}$	CTLs pre-activated by epitope-presenting cells (infected $T_H$ /C cells or pAPCs)
$T_{C[Pr2]}$	CTLs receiving co-stimulatory cytokines
$T_{C[a]}$	Fully activated CTLs
$D_{[r]}$	Resting pAPCs
$D_{[w]}$	pAPC presenting a wild-type epitope
$D_{[48]}$	pAPC presenting a T-cell ( $T_H$ /CTL)-escape epitope
$V_w$	Load of wild-type virus
$V_{48}$	Load of T-cell ( $T_H$ /CTL) escape virus
$C_{[w]}$	C cells infected with the wild-type virus (control model)
$C_{[48]}$	C cells infected with the $T_H$ /CTL-escape mutant (control model)

## List of parameters in the models with values used and references

Parameter	Definition	Values	Refs
$\rho_4$	Proliferation rate of $T_H$ cells	$0.05 \text{ day}^{-1}$	[1]
$C_{4[r]}^0$	Homeostatic concentration of resting $T_H$ cells	$1000 / \mu\text{L}$	[2]
$\Gamma_{4[r]}$	Death rate of resting $T_H$ cells	$0.005 \text{ day}^{-1}$	[1]
$\Gamma_{4[a]}$	Death rate of activated $T_H$ cells	$0.1 \text{ day}^{-1}$	[1]
$\Gamma_{4[i]}$	Death rate of infected $T_H$ cells	$1 \text{ day}^{-1}$	[3–8]
$\rho_8$	Proliferation rate of CTLs	$\rho_4$	
$C_{8[r]}^0$	Homeostatic concentration of resting CTLs	$3000 / \mu\text{L}$	
$\Gamma_{8[r]}$	Death rate of resting CTLs	$\Gamma_{4[r]}$	
$\Gamma_{8[pr]}$	Death rate of pre-activated CTLs	$\Gamma_{4[r]}$	
$\Gamma_{8[a]}$	Death rate of activated CTLs	$\Gamma_{4[a]}$	
$\rho_D$	Proliferation rate of pAPCs	$\rho_4$	
$C_{D[r]}^0$	Homeostatic concentration of pAPCs	$100 / \mu\text{L}$	[9]
$\Gamma_{D[r]}$	Death rate of resting pAPCs	$\Gamma_{4[r]}$	
$\Gamma_{D[a]}$	Death rate of epitope-presenting pAPCs	$\Gamma_{4[a]}$	
$\rho_C$	Proliferation rate of C cells (control model)	$\rho_4$	
$C_C^0$	Homeostatic concentration of C cells (control model)	set-point $T_{H[a]}$	
$\Gamma_C$	Death rate of C cells (control model)	$\Gamma_{4[a]}$	
$\Gamma_{C[i]}$	Death rate of infected C cells (control model)	$\Gamma_{4[w]}$	
$a_4$	pAPC-mediated rate of $T_H$ cell activation	$0-1 \text{ day}^{-1}$	
$a_{8'}$	Pre-activation rate of CTLs receiving co-stimulatory cytokines	$a_4$	
$a_8$	Pre-activation rate of CTLs by infected $T_H$ (C) cells	$a_4$	
$a_{8D}$	Pre-activation rate of CTLs by pAPCs	$a_4$	
$b$	Fraction of resting $T_H$ cells undergoing background activation	$0-1 \text{ day}^{-1}$	
$d$	Trans-infection probability	$0-1$	
$k$	CTL-mediated rate of infected cell killing	$0.1 \text{ day}^{-1}$	[10]
$\sigma$	Viral infectivity	$1 \text{ day}^{-1}$	
$\sigma_D$	Rate of virion absorption by pAPCs	$1 \text{ day}^{-1}$	
$\alpha$	Virus production rate in infected cells	$5000 \Gamma_{4[i]} \text{ day}^{-1}$	[11–14]
$\Gamma_V$	Inactivation rate of free virions	$15 \text{ day}^{-1}$	[3,7,15]
$\mu$	Mutation rate to escape virus	$10^{-5}$	[16]

## HIV immune activation model

### Description

Resting  $T_H$  cells replicate with rate constant  $\rho_4$  if their concentration is below an homeostatic goal  $C_{4[r]}^0$  and do not replicate otherwise (modeled with a step function  $\Theta$ ). The homeostatic goal applies to resting cells only and that, therefore, the number of activated  $T_H$  is not limited, allowing for clonal expansion. Resting and activated  $T_H$  cells die at rates  $\Gamma_{4[r]}$  and  $\Gamma_{4[a]}$ , respectively.

Background activation of  $T_H$  cells occurs at a rate  $bT_{H[r]}$ , and HIV-specific activation occurs at a rate  $T_{H[r]} \left( \frac{D_{[w]}}{T_{H[r]} + D_{[w]}} \right)$  when resting  $T_H$  cells contact pAPCs presenting the wild-type epitope. Escape mutants do not trigger  $T_H$  cell activation. The activation rate depends on the relative abundance of each cell type. For instance, if pAPCs are rare compared to resting  $T_H$  cells, the rate of  $T_H$  cell activation is essentially limited by pAPC availability. This type of expression is used for all cell-cell and virus-cell interactions in the model.

Of the total number of activated cells, a fraction  $d$  becomes concomitantly infected with the wild-type virus and a fraction  $1 - d$  is not infected but becomes susceptible to infection with the wild-type or the escape mutant. Activated  $T_H$  cells are infected at a rate  $\sigma T_{H[a]} \left( \frac{V_w + V_{48}}{T_{H[a]} + V_w + V_{48}} \right)$ . As above, infection rates depend on the relative abundance of each virus and cell. When virions are more abundant than target cells, cells become a limiting resource. When cellular resources are limited the infection rate of the wild-type decreases as the escape mutant becomes more abundant, and vice-versa. Therefore, there is competition among viruses for cells.

Infected cells are killed by the wild-type virus and escape mutant at rates  $\Gamma_{4[i]} T_{H[w]}$  and  $\Gamma_{4[i]} T_{H[48]}$ , respectively. In addition, cells infected by the wild-type virus are lysed by activated CTLs at a rate  $k T_{C[a]} \left( \frac{T_{H[w]}}{T_{C[a]} + T_{H[w]}} \right)$ , whereas cells infected with the escape mutant are not lysed by CTLs.

Resting CTLs replicate with rate constant  $\rho_8$  if their concentration is below their homeostatic goal (i.e. if  $C_{8[r]}^0 - T_{C[r]} > 0$ ) and do not replicate otherwise. Their death rate constant is  $\Gamma_{8[r]}$ . As in the case of  $T_H$  cells, the homeostatic goal applies to resting cells only. CTLs become pre-activated (Pr1) by recognizing the wild-type epitope presented by infected cells or pAPCs, at rates  $a_8 T_{C[r]} \left( \frac{T_{H[w]}}{T_{C[r]} + T_{H[w]}} \right)$  and  $a_{8D} T_{C[r]} \left( \frac{D_{[w]}}{T_{C[r]} + D_{[w]}} \right)$ , respectively. These pre-activated cells undergo full activation after receiving a co-stimulatory signal from activated (non-infected)  $T_H$  cells, which occurs at a rate  $a_8 T_{C[Pr1]} \left( \frac{T_{H[a]}}{T_{C[Pr1]} + T_{H[a]}} \right)$ . Resting CTLs can also

become pre-activated by the co-stimulatory signal (Pr2) and then become fully activated after recognizing the wild-type epitope. Activated CTLs die with rate constant  $\Gamma_{8[a]}$ .

Resting pAPCs replicate with rate constant  $\rho_D$  if their total concentration is below their homeostatic goal, i.e. if  $C_{D[r]}^0 - D_{[r]} - D_{[w]} - D_{[48]} > 0$ , and do not replicate otherwise. Notice that here the homeostatic goal applies to all cells, such that there is no clonal expansion. pAPCs become activated after processing wild-type or escape mutant virions at a rate  $\sigma_D D_{[r]} \left( \frac{V_w + V_{48}}{D_{[r]} + V_w + V_{48}} \right)$ . Resting and activated pAPCs die with rate constants  $\Gamma_{D[r]}$  and  $\Gamma_{D[a]}$ , respectively.

$T_H$  cells infected with the wild-type virus produce virions at a rate  $\alpha T_{H[w]}$ . A fraction  $\mu$  of the viral progeny is constituted by escape mutants and a fraction  $(1 - \mu)$  by wild-type viruses.  $T_H$  cells infected with the escape mutant produce virions at a rate  $\alpha T_{H[48]}$ . Back mutation from the escape mutant to the wild-type is neglected. Virions are inactivated with rate constant  $\Gamma_V$ .

### Equations

$$\frac{d}{dt} T_{H[r]} = \rho_4 \Theta \left( C_{4[r]}^0 - T_{H[r]} \right) - \Gamma_{4[r]} T_{H[r]} - b T_{H[r]} - a_4 T_{H[r]} \left( \frac{D_{[w]}}{T_{H[r]} + D_{[w]}} \right)$$

$$\frac{d}{dt} T_{H[a]} = -\Gamma_{4[a]} T_{H[a]} + b T_{H[r]} + a_4 (1 - d) T_{H[r]} \left( \frac{D_{[w]}}{T_{H[r]} + D_{[w]}} \right) - \sigma T_{H[a]} \left( \frac{V_w + V_{48}}{T_{H[a]} + V_w + V_{48}} \right)$$

$$\frac{d}{dt} T_{H[w]} = -\Gamma_{4[i]} T_{H[w]} + a_4 d T_{H[r]} \left( \frac{D_{[w]}}{T_{H[r]} + D_{[w]}} \right) + \sigma T_{H[a]} \left( \frac{V_w}{T_{H[a]} + V_w + V_{48}} \right) - k T_{C[a]} \left( \frac{T_{H[w]}}{T_{C[a]} + T_{H[w]}} \right)$$

$$\frac{d}{dt} T_{H[48]} = -\Gamma_{4[i]} T_{H[48]} + \sigma T_{H[a]} \left( \frac{V_{48}}{T_{H[a]} + V_w + V_{48}} \right)$$

$$\frac{d}{dt} T_{C[r]} = \rho_8 \Theta \left( C_{8[r]}^0 - T_{C[r]} \right) - \Gamma_{8[r]} T_{C[r]} - a_8 T_{C[r]} \left( \frac{T_{H[w]}}{T_{C[r]} + T_{H[w]}} \right) - a_{8D} T_{C[r]} \left( \frac{D_{[w]}}{T_{C[r]} + D_{[w]}} \right) - a_8 T_{C[r]} \left( \frac{T_{H[a]}}{T_{C[r]} + T_{H[a]}} \right)$$

$$\frac{d}{dt} T_{C[Pr1]} = -\Gamma_{8[pr]} T_{C[Pr1]} + a_8 T_{C[r]} \left( \frac{T_{H[w]}}{T_{C[r]} + T_{H[w]}} \right) + a_{8D} T_{C[r]} \left( \frac{D_{[w]}}{T_{C[r]} + D_{[w]}} \right) - a_8 T_{C[Pr1]} \left( \frac{T_{H[a]}}{T_{C[Pr1]} + T_{H[a]}} \right)$$

$$\frac{d}{dt} T_{C[Pr2]} = -\Gamma_{8[pr]} T_{C[Pr2]} - a_8 T_{C[Pr2]} \left( \frac{T_{H[w]}}{T_{C[Pr2]} + T_{H[w]}} \right) - a_{8D} T_{C[Pr2]} \left( \frac{D_{[w]}}{T_{C[Pr2]} + D_{[w]}} \right) + a_8 T_{C[r]} \left( \frac{T_{H[a]}}{T_{C[r]} + T_{H[a]}} \right)$$

$$\frac{d}{dt} T_{C[a]} = -\Gamma_{8[a]} T_{C[a]} + a_8 T_{C[Pr2]} \left( \frac{T_{H[w]}}{T_{C[Pr2]} + T_{H[w]}} \right) + a_{8D} T_{C[Pr2]} \left( \frac{D_{[w]}}{T_{C[Pr2]} + D_{[w]}} \right) + a_8 T_{C[Pr1]} \left( \frac{T_{H[a]}}{T_{C[Pr1]} + T_{H[a]}} \right)$$

$$\frac{d}{dt} D_{[r]} = \rho_D \Theta \left( C_{D[r]}^0 - D_{[r]} - D_{[w]} - D_{[48]} \right) - \Gamma_{D[r]} D_{[r]} - \sigma_D D_{[r]} \left( \frac{V_w + V_{48}}{D_{[r]} + V_w + V_{48}} \right)$$

$$\frac{d}{dt} D_{[w]} = -\Gamma_{D[a]} D_{[w]} + \sigma_D D_{[r]} \left( \frac{V_w}{D_{[r]} + V_w + V_{48}} \right)$$

$$\frac{d}{dt}D_{[48]} = -\Gamma_{D_{[a]}}D_{[48]} + \sigma_D D_{[r]} \left( \frac{V_{48}}{D_{[r]}+V_w+V_{48}} \right)$$

$$\frac{d}{dt}V_{[w]} = -\Gamma_V V_{[w]} - \sigma T_{H[a]} \left( \frac{V_w}{T_{H[a]}+V_w+V_{48}} \right) - \sigma_D D_{[r]} \left( \frac{V_w}{D_{[r]}+V_w+V_{48}} \right) + (1 - \mu)\alpha T_{H[w]}$$

$$\frac{d}{dt}V_{[48]} = -\Gamma_V V_{[48]} - \sigma T_{H[a]} \left( \frac{V_{48}}{T_{H[a]}+V_w+V_{48}} \right) - \sigma_D D_{[r]} \left( \frac{V_{48}}{D_{[r]}+V_w+V_{48}} \right) + \alpha T_{H[48]} + \mu\alpha T_{H[w]}$$

## Control model

### Description

The control model is identical to the HIV model except for the fact that the virus infects a cell type C which is not part of the cellular immune system, instead of  $T_H$  cells. C cells replicate with rate constant  $\rho_C$  if their concentration is below their homeostatic goal, i.e. if  $C_C^0 - C_{[r]} - C_{[w]} - C_{[48]} > 0$ , and do not replicate otherwise. Since C cells do not need to be activated to become susceptible to the virus, the pool of available cells is higher than in the HIV model. To compensate for this, we adjusted the homeostatic goal for C cells to obtain the same number of susceptible cells in the HIV and control models at set point, and thus obtain similar set-point viral titers.

### Equations

$$\frac{d}{dt}T_{H[r]} = \rho_4 \Theta \left( C_{4[r]}^0 - T_{H[r]} \right) - \Gamma_{4[r]} T_{H[r]} - b T_{H[r]} - a_4 T_{H[r]} \left( \frac{D_{[w]}}{T_{H[r]}+D_{[w]}} \right)$$

$$\frac{d}{dt}T_{H[a]} = -\Gamma_{4[a]} T_{H[a]} + b T_{H[r]} + a_4 T_{H[r]} \left( \frac{D_{[w]}}{T_{H[r]}+D_{[w]}} \right)$$

$$\frac{d}{dt}T_{C[r]} = \rho_8 \Theta \left( C_{8[r]}^0 - T_{C[r]} \right) - \Gamma_{8[r]} T_{C[r]} - a_8 T_{C[r]} \left( \frac{C_{[w]}}{T_{C[r]}+C_{[w]}} \right) - a_{8D} T_{C[r]} \left( \frac{D_{[w]}}{T_{C[r]}+D_{[w]}} \right) - a_{8T} T_{C[r]} \left( \frac{T_{H[a]}}{T_{C[r]}+T_{H[a]}} \right)$$

$$\frac{d}{dt}T_{C[Pr1]} = -\Gamma_{8[pr]} T_{C[Pr1]} + a_8 T_{C[r]} \left( \frac{C_{[w]}}{T_{C[r]}+C_{[w]}} \right) + a_{8D} T_{C[r]} \left( \frac{D_{[w]}}{T_{C[r]}+D_{[w]}} \right) - a_{8T} T_{C[Pr1]} \left( \frac{T_{H[a]}}{T_{C[Pr1]}+T_{H[a]}} \right)$$

$$\frac{d}{dt}T_{C[Pr2]} = -\Gamma_{8[pr]} T_{C[Pr2]} - a_8 T_{C[Pr2]} \left( \frac{C_{[w]}}{T_{C[Pr2]}+C_{[w]}} \right) - a_{8D} T_{C[Pr2]} \left( \frac{D_{[w]}}{T_{C[Pr2]}+D_{[w]}} \right) + a_{8T} T_{C[r]} \left( \frac{T_{H[a]}}{T_{C[r]}+T_{H[a]}} \right)$$

$$\frac{d}{dt}T_{C[a]} = -\Gamma_{8[a]} T_{C[a]} + a_8 T_{C[Pr2]} \left( \frac{C_{[w]}}{T_{C[Pr2]}+C_{[w]}} \right) + a_{8D} T_{C[Pr2]} \left( \frac{D_{[w]}}{T_{C[Pr2]}+D_{[w]}} \right) + a_{8T} T_{C[Pr1]} \left( \frac{T_{H[a]}}{T_{C[Pr1]}+T_{H[a]}} \right)$$

$$\frac{d}{dt}D_{[r]} = \rho_D \Theta \left( C_{D[r]}^0 - D_{[r]} - D_{[48]} \right) - \Gamma_{D[r]} D_{[r]} - \sigma_D D_{[r]} \left( \frac{V_w+V_{48}}{D_{[r]}+V_w+V_{48}} \right)$$

$$\frac{d}{dt}D_{[w]} = -\Gamma_{D[a]} D_{[w]} + \sigma_D D_{[r]} \left( \frac{V_w}{D_{[r]}+V_w+V_{48}} \right)$$

$$\frac{d}{dt}D_{[48]} = -\Gamma_{D_{[a]}}D_{[48]} + \sigma_D D_{[r]} \left( \frac{V_{48}}{D_{[r]}+V_w+V_{48}} \right)$$

$$\frac{d}{dt}V_{[w]} = -\Gamma_V V_{[w]} - \sigma_C \left( \frac{V_w}{C+V_w+V_{48}} \right) - \sigma_D D_{[r]} \left( \frac{V_w}{D_{[r]}+V_w+V_{48}} \right) + (1 - \mu)\alpha C_{[w]}$$

$$\frac{d}{dt}V_{[48]} = -\Gamma_V V_{[48]} - \sigma_C \left( \frac{V_{48}}{C+V_w+V_{48}} \right) - \sigma_D D_{[r]} \left( \frac{V_{48}}{D_{[r]}+V_w+V_{48}} \right) + \alpha C_{[48]} + \mu\alpha C_{[w]}$$

$$\frac{d}{dt}C = \rho_C \Theta(C_C^0 - C_{[r]} - C_{[w]} - C_{[48]}) - \Gamma_C C - \sigma_C \left( \frac{V_w+V_{48}}{C+V_w+V_{48}} \right)$$

$$\frac{d}{dt}C_{[w]} = -\Gamma_{C_{[i]}} C_{[w]} + \sigma_C \left( \frac{V_w}{C+V_w+V_{48}} \right) - kT_{C_{[a]}} \left( \frac{C_{[w]}}{T_{C_{[a]}}+C_{[w]}} \right)$$

$$\frac{d}{dt}C_{[48]} = -\Gamma_{C_{[i]}} C_{[48]} + \sigma_C \left( \frac{V_{48}}{C+V_w+V_{48}} \right)$$

## References

1. Macallan DC, Asquith B, Irvine AJ, Wallace DL, Worth A, et al. (2003) Measurement and modeling of human T cell kinetics. *Eur J Immunol* 33: 2316-2326.
2. Bofill M, Janossy G, Lee CA, MacDonald-Burns D, Phillips AN, et al. (1992) Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. *Clin Exp Immunol* 88: 243-252.
3. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, et al. (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. *Nature* 373: 123-126.
4. Markowitz M, Louie M, Hurley A, Sun E, Di MM, et al. (2003) A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. *J Virol* 77: 5037-5038.
5. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. *Science* 271: 1582-1586.
6. Rodrigo AG, Shpaer EG, Delwart EL, Iversen AK, Gallo MV, et al. (1999) Coalescent estimates of HIV-1 generation time in vivo. *Proc Natl Acad Sci USA* 96: 2187-2191.
7. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, et al. (1995) Viral dynamics in human immunodeficiency virus type 1 infection. *Nature* 373: 117-122.
8. Althaus CL, De Vos AS, de Boer RJ (2009) Reassessing the human immunodeficiency virus type 1 life cycle through age-structured modeling: life span of infected cells, viral generation time, and basic reproductive number, R0. *J Virol* 83: 7659-7667.
9. Haller HJ, Zapas JL, Elias EG (2005) Dendritic cell counts in the peripheral blood of healthy adults. *Am J Hematol* 78: 314-315.
10. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, et al. (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. *J Exp Med* 206: 1253-1272.
11. Chen HY, Di MM, Perelson AS, Ho DD, Zhang L (2007) Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. *Proc Natl Acad Sci USA* 104: 19079-19084.

12. De Boer RJ, Ribeiro RM, Perelson AS (2010) Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues. *PLoS Comput Biol* 6: e1000906.
13. Hockett RD, Kilby JM, Derdeyn CA, Saag MS, Sillers M, et al. (1999) Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. *J Exp Med* 189: 1545-1554.
14. Reilly C, Wietgreffe S, Sedgewick G, Haase A (2007) Determination of simian immunodeficiency virus production by infected activated and resting cells. *AIDS* 21: 163-168.
15. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, et al. (1999) Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. *Lancet* 354: 1782-1785.
16. Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R (2010) Viral mutation rates. *J Virol* 84: 9733-9748.